¾«Æ·¹ú²úÒ»Çø¶þÇøÌÒÉ«

Award

Voelker’s work, integrity
draw praise

He won ¾«Æ·¹ú²úÒ»Çø¶þÇøÌÒÉ« Avanti Award in Lipids
Stefan Lukianov
April 1, 2018

, director of research of the pulmonary division in the department of medicine at and a professor of biochemistry and molecular genetics at the , will receive the from the ¾«Æ·¹ú²úÒ»Çø¶þÇøÌÒÉ«. The award recognizes his work on lipid metabolism, nonvesicular phospholipid trafficking and phospholipid regulation of innate immunity.

Voelker has made “seminal contributions” to the field of lipid biology, of Rutgers University wrote in his nomination letter, adding that he has collaborated several times with Voelker “because of his expertise and keen insight into the molecular genetics and biochemistry of lipids.”

“It is an honor to receive the Avanti Award in Lipids, and I am indebted to my mentors, Ten-ching Lee, Fred Snyder and Eugene P. Kennedy for providing exceptional training. I also must recognize the students and fellows whose insights and dedication have been an essential part of my laboratory.”

Dennis R. Voelker

The Voelker group has focused for 37 years on such topics as phospholipid-protein interactions, lipid metabolism, lipid transport and lipid enzymology, using a variety of techniques in virology, biochemistry and molecular biology. His early research provided insight into the mechanisms of phospholipid transport between organelles, especially between the endoplasmic reticulum and mitochondria. Phospholipids are major constituents of cell membranes, consisting of a hydrophilic head group linked by a phosphodiester to a hydrophobic segment containing esterified fatty acids. The amphipathic nature of phospholipids enables them to spontaneously form bilayer structures, which are the hallmark of biological membranes. Using biochemical and genetic approaches, Voelker’s group has identified genes and proteins important for the phospholipid aspect of membrane assembly.

Most recently, the Voelker lab has made important advances in understanding how phospholipids inhibit innate immune processes and respiratory viral infections. The lab found that there are high-affinity interactions between anionic phospholipids and enveloped respiratory viruses, such as respiratory syncytial virus and influenza A virus, that inhibit viral infection.

These phospholipids also bind to Toll-like receptors, which are crucial for triggering inflammatory processes of the innate immune system. This interaction inhibits the inflammatory response that accompanies infection and injury, thereby protecting the lungs from the damaging effects of prolonged inflammation.

In addition to Voelker’s outstanding research, Carman mentioned his superb mentorship. Several of Carman’s students worked with Voelker, whose “guidance in research excellence and communication propelled their careers in academia or the pharmaceutical industry,” Carman wrote.

, chair of the department of medicine at National Jewish Health, described Voelker in a letter supporting the nomination as an integral member of their research community. “At National Jewish he is highly regarded by faculty, fellows and students for his scientific acumen, integrity and insight,” Martin wrote, adding that Voelker’s presentations there are “heavily attended and reach all researchers from basic to clinical in an engaging and enlightening scientific manner.”

Voelker earned his Ph.D. from the University of Tennessee-Oak Ridge National Laboratory Graduate School of Biomedical Sciences in 1978. He completed his postdoctoral training at Harvard Medical School in 1981, afterward becoming an assistant professor in the department of biochemistry, biophysics and genetics at the University of Colorado Health Sciences Center as well as an assistant faculty member in the department of medicine at the National Jewish Center for Immunology and Respiratory Medicine. Voelker was promoted to full professor in 1994.

Voelker receivee his award during the 2018 ASBMB Annual Meeting in San Diego, and delivered an award lecture on phospholipid regulation of inflammatory processes and viral infection. 

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Stefan Lukianov

Stefan Lukianov is the founder and chief executive officer of Salve Therapeutics.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Understanding the roles of extracellular matrix and vesicles in valvular disease
Profile

Understanding the roles of extracellular matrix and vesicles in valvular disease

Oct. 30, 2025

MOSAIC scholar Cassandra Clift uses mass spectrometry and multiomics to study cardiovascular calcification and collagen dysregulation, bridging her background in bioengineering and biology to investigate extracellular vesicles and heart disease.

Learning, leading and lifting others
Profile

Learning, leading and lifting others

Oct. 23, 2025

Tigist Tamir’s journey from aspiring astronaut in Ethiopia to cancer researcher at the University of North Carolina highlights the power of mentorship, persistence and curiosity in shaping a scientific career focused on discovery and equity.

Biochemists and molecular biologists sweep major 2025 honors
News

Biochemists and molecular biologists sweep major 2025 honors

Oct. 20, 2025

Recent Nobel, MacArthur and Kimberly Prize honorees highlight the power of biochemistry and molecular biology to drive discovery, including immune tolerance, vaccine design and metabolic disease, and to advance medicine and improve human health.

Subramanian receives electron microscopy honor
Member News

Subramanian receives electron microscopy honor

Oct. 13, 2025

He delivered remarks at the International Conference on Electron Microscopy in Bangalore, India.

Bioart for fall: From order to disorder
Art

Bioart for fall: From order to disorder

Oct. 7, 2025

The cover of the fall issue of ASBMB Today was created by ASBMB member, Soutick Saha, a bioinformatics developer at Wolfram Alpha LLC.

Doudna wins Priestley Medal
Member News

Doudna wins Priestley Medal

Oct. 6, 2025

She will receive a $20,000 research grant and will formally accept the honor at the ACS Spring 2026 conference.